Business Wire

NY-CORSEARCH

31.1.2020 13:02:09 CET | Business Wire | Press release

Share
Corsearch Announces Acquisition of Pointer Brand Protection

Corsearch, a trademark and brand protection solutions leader, is pleased to announce the acquisition of Pointer Brand Protection, a prominent provider of anti-counterfeiting and brand protection services. The acquisition further extends Corsearch’s fast-growing brand protection offering and provides a comprehensive new service for brand owners and legal professionals. For the first time, a consolidated suite of technologically advanced solutions will support the research, clearance, monitoring, investigative, and enforcement needs of the brand lifecycle.

From counterfeiting and piracy to gray trade and brand impersonation, estimates suggest that a staggering one in four online purchases involve brand infringement. With global eCommerce expected to reach 4.5 trillion U.S. dollars by 2021, the need for online brand protection to fight these threats has never been more urgent. It is an issue that is growing in tandem with total global trade, with some reports projecting that by 2022 counterfeiting and piracy could result in the loss of 4.2 trillion U.S. dollars and the endangerment of 5.4 million legitimate jobs.

A global problem needs global solutions, and the addition of Pointer Brand Protection into the Corsearch family aligns the technological capabilities and extensive networks of the entire group into a brand establishment and protection provider with unmatched coverage.

For many businesses, the digital environment has become so complex that establishing and protecting brands is too fragmented and time consuming to be manageable. To combat this effectively, brand owners and legal professionals require technological leadership and innovative solutions to implement a strong, proactive brand protection program. The Corsearch Brand Protection platform will provide an entirely new service offering which combines the very best teams, expertise, and technologies from both Pointer and from previous Corsearch acquisition, Yellow Brand Protection. In addition to Corsearch’s existing services, the new platform will provide brands with a full-service solution combining everything from trademark research and clearing to machine learning, automated marketplace enforcement, and end-to-end investigations. To fight infringements at their source, the new team will also include the largest China-based online brand protection department in the industry.

“Since 2008, Pointer has worked with hundreds of globally-renowned brands to protect them from infringement and abuse,” said Pointer CEO, Robert Stolk. “The industry is becoming more challenging every day and brands require technologies and services that can outpace that. Joining forces with Corsearch means securing the ability to innovate in a way that anticipates the needs of customers while also benefiting from Corsearch’s trusted industry presence.”

Corsearch’s CEO, Tobias Hartmann, commented, “We are thrilled to bring the brightest minds in online brand protection together and define the future of this industry. With this strategic acquisition Corsearch becomes the only provider to support the needs of IP and brand professionals throughout the trademark lifecycle.”

About Corsearch

Corsearch (www.corsearch.com ) is a leading provider of clearance and online brand protection solutions for trademark and brand professionals. With highly trained researchers, an expansive global content set, and customer-focused technology tools available through the Corsearch platform, Corsearch empowers its customers with powerful brand solutions in an increasingly complex business environment.

Founded in 1949 and headquartered in New York, Corsearch now has over 450 employees working across its 10 global offices. Corsearch has advised 43 of the world’s top 50 brands and has in excess of 5,000 clients around the world.

For more information please contact Stephen Stolfi, Chief Commercial Officer, or visit corsearch.com.

About Pointer

Pointer Brand Protection (https://pointerbrandprotection.com/ ) has been defending global brands from counterfeiting and brand abuse since 2008. With more than 120 employees working from offices in Amsterdam, Shanghai, New York, and London, Pointer is an industry leader in the fight against brand infringement. Pointer offers holistic and bespoke anti-counterfeiting solutions that include online-to-offline investigations, test purchasing services, dedicated brand protection analysts, and a proprietary software platform for the removal of infringements. Its mission is to clean the online marketplace in order to create safety for consumers, to increase the integrity of hard-working brands, and to reduce the negative societal impact of counterfeiting.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye